Shopping Cart
- Remove All
- Your shopping cart is currently empty
J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $53 | 5 days |
Description | J22352, a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM, enhances anticancer effects in glioblastoma by promoting HDAC6 degradation. It does so by inhibiting autophagy and stimulating the antitumor immune response, further restoring host antitumor activity through the reduction of PD-L1's immunosuppressive activity. |
Targets&IC50 | HDAC6:4.7 nM |
In vitro | J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance. J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner. |
In vivo | J22352 is well tolerated in mice.J22352 (10?mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. |
Molecular Weight | 415.44 |
Formula | C24H21N3O4 |
Cas No. | 2252395-44-9 |
Relative Density. | 1.343 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (300.89 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.